Patient case: 70-year-old female with breast cancer; genetic feature: AURKA amplification

Clinical trial: MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)

Summary: Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk.
  The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women:
  -  With a moderate risk of breast cancer progression (women with an early "Luminal A" tumor) = Group A.
  -  With a high risk of breast cancer progression (women with an early "Luminal B" or basal tumor) = Group B.

Detailed description: Breast cancer is one of the most frequent and the second cause of mortality for women in the world. Breast is a complex organ which has several changes (puberty, pregnancy and menopause). These modifications are controlled by numerous signals as those transmitted by the oestrogens. They are possible through the presence of stem cells in the mammary gland which are able to reply to these signals and can be the target of alterations leading to cancer cells occurence. Breast tumors are composed of complex entities of different kinds of cancer and normal cells which constitute the tumor micro-environment including the immune system cells. This micro-environment transmits a lot of signals to cancer cells and particularly stem cells which can contribute to their survival, the tumor progression and interfere with the treatments efficacy.
  The detection of the major deregulation of BMP2 synthesis by mammary micro-environment cells may be a reliable and early biomarker of carcinogens exposure and an indicator of a high risk of developing a luminal type breast cancer.
  The immune micro-environment, which has an impact on solid cancer patients' survival, should be taken into consideration for new therapeutic strategies.
  Some infiltrating tumour immune cells, as macrophages (TAM) or regulating T and B cells, have shown their key role in tumour escape and metastases apparition. It is relevant to associate the evaluation of immune infiltrate to the breast stem cells in early stage tumours since the literature suggests a functional interaction of these two cellular compartments, particularly in the glioblastoma and the prostate cancer. It seems that mammary stem cells are a major element in the comprehension of breast carcinogenesis but also in the possibilities of repairing the mammary tissue controlling the mammary carcinogenesis.
  It is fundamental to clarify the role of stem cells and immunity. Our hypothesis is that breast stem cells are altered in women having a high risk of cancer progression. They would be responsible for a reduced activity of cellular repair and/or contribute to tumour development.
  MACSSI project consists in isolating, quantifying and characterizing the breast stem cells and the isolated immune cells of samples obtained for the prophylactic mastectomy in women presenting different tumour progression risks.
  The results will be compared to normal samples already collected in women who had a breast reduction.

Eligibility: Inclusion Criteria:
  -  Age ≥ 18 years
  -  Patient requiring a breast surgery (total mastectomy) of an early stage tumour classified as :
  -  Luminal A (Arm A) : Patients with a moderate risk of breast cancer progression or,
  -  Luminal B or Basal (Arm B) : Patients with a high risk of breast cancer progression
  -  Systemic treatment not initiated
  -  Breast cup size ≥ C
  -  Informed and signed consent.
  Exclusion Criteria:
  -  Neo-adjuvant chemotherapy or hormonotherapy
  -  History of breast irradiation
  -  Pregnant or breastfeeding woman
  -  Patient under tutorship or curatorship
  -  Patient who underwent a lumpectomy with a level-2 oncoplastic surgery (ex: breast reduction with an inverted-T remodeling)
  -  Any other prior anti-tumor treatment
  -  Other medical pathology which may interfere with the biologic evaluation, especially chronic auto-immune diseases.

Relevance to patient case: not relevant